It's Time to Expand Chlamydia Treatment for Gay and Bisexual Men.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 33685878.
- Also identified by DOI 10.1370/afm.2624 and PMC identifier 7939718.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Expedited partner therapy involves prescribing sexually transmitted infection (STI) treatment for a patient's partner(s) without seeing the partner. It is approved for heterosexual partners of patients with chlamydia in most states. However, the Centers for Disease Control and Prevention recommends against expedited partner therapy in men-who-have-sex-with-men (MSM), citing limited data in this population and concerns that expedited partner therapy could discourage comprehensive STI testing, thereby driving increased HIV transmission. In this piece, we describe the case of a 33-year-old gay man on HIV pre-exposure prophylaxis (PrEP) whose cycle of chlamydia reinfection might have been prevented by expedited partner therapy. His case highlights how new HIV prevention strategies-including PrEP and Treatment as Prevention-challenge the assumption that all MSM with chlamydia are at risk for HIV. Until more data on expedited partner therapy in MSM are available, clinicians should incorporate characteristics of patients' sexual networks in weighing the risks and benefits of expedited partner therapy.
Medical subject headings
- Anti-Bacterial Agents
- Bisexuality
- Chlamydia Infections
- Contact Tracing
- Healthcare Disparities
- Homosexuality, Male
- Sexual Partners
- Sexually Transmitted Diseases